As filed with the Securities and Exchange Commission on March 5, 2020
RegistrationNo. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORMS-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Fulcrum Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
| Delaware | 47-4839948 | |
(State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | |
26 Landsdowne Street Cambridge, Massachusetts | 02139 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
2019 Stock Incentive Plan
2019 Employee Stock Purchase Plan
(Full Title of the Plan)
Robert J. Gould, Ph.D.
President and Chief Executive Officer
Fulcrum Therapeutics, Inc.
26 Landsdowne Street
Cambridge, Massachusetts 02139
(Name and Address of Agent For Service)
(617) 651-8851
(Telephone Number, Including Area Code, of Agent For Service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, anon-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act.
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
| Emerging growth company | ☒ | |||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
| ||||||||
Title of securities to be registered | Amount to be registered(1) | Proposed maximum offering price per share | Proposed maximum aggregate offering price | Amount of registration fee | ||||
Common Stock, par value $0.001 per share | 1,166,775(2) | $19.15(3) | $22,343,741.25(3) | $2,900.22 | ||||
| ||||||||
| ||||||||
| (1) | In accordance with Rule 416 under the Securities Act of 1933, as amended, this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. |
| (2) | Consists of an additional (i) 933,420 shares issuable under the 2019 Stock Incentive Plan and (ii) 233,355 shares issuable under the 2019 Employee Stock Purchase Plan. |
| (3) | Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act of 1933, as amended, and based upon the average of the high and low sale prices of the Registrant’s Common Stock as reported on the Nasdaq Global Market on February 28, 2020. |
STATEMENT OF INCORPORATION BY REFERENCE
This Registration Statement on FormS-8, relating to the 2019 Stock Incentive Plan of Fulcrum Therapeutics, Inc. (the “Registrant”) and the 2019 Employee Stock Purchase Plan of the Registrant, is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on FormS-8 relating to the 2019 Stock Incentive Plan and the 2019 Employee Stock Purchase Plan has previously been filed and is effective. Accordingly, this Registration Statement incorporates by reference the contents of the Registration Statement onFormS-8, File No. 333-233452, filed with the Securities and Exchange Commission on August 26, 2019 by the Registrant, relating to the Registrant’s 2016 Stock Incentive Plan, as amended, 2019 Stock Incentive Plan and 2019 Employee Stock Purchase Plan, except for Item 8, Exhibits.
| Item 8. | Exhibits |
| * | Filed herewith |
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on FormS-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 5th day of March, 2020.
| FULCRUM THERAPEUTICS, INC. | ||
| By: | /s/ Robert J. Gould | |
| Robert J. Gould, Ph.D. | ||
| President and Chief Executive Officer | ||
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of Fulcrum Therapeutics, Inc., hereby severally constitute and appoint Robert J. Gould and Bryan Stuart, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on FormS-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Fulcrum Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature | Title | Date | ||
/s/ Robert J. Gould Robert J. Gould, Ph.D. | President and Chief Executive Officer, Director (Principal Executive Officer) | March 5, 2020 | ||
/s/ Bryan Stuart Bryan Stuart | Chief Operating Officer (Principal Financial Officer) | March 5, 2020 | ||
/s/ Peter Thomson Peter Thomson | Vice President, Finance & Accounting (Principal Accounting Officer) | March 5, 2020 | ||
/s/ Mark Levin Mark Levin | Chairman of the Board | March 5, 2020 | ||
/s/ James J. Collins James J. Collins, Ph.D. | Director | March 5, 2020 | ||
/s/ Katina Dorton Katina Dorton | Director | March 5, 2020 | ||
/s/ Alan Ezekowitz Alan Ezekowitz, MBChB, D. Phil | Director | March 5, 2020 | ||
/s/ James Geraghty James Geraghty | Director | March 5, 2020 | ||
/s/ Kate Haviland Kate Haviland | Director | March 5, 2020 | ||
